Emily Lebow, MD
@EmilyLebow
Followers
280
Following
681
Media
3
Statuses
61
Radiation Oncologist @PennMedicine @PennRadOnc Alum @MSK_RadOnc @Harvardmed @Penn
University of Pennsylvania
Joined June 2021
RT @ASTRO_org: Congratulations to Iris Gibbs, MD, FASTRO; Helen Shih, MD, MS, MPH, FASTRO; & Joachim Yahalom, MD, FASTRO on their 2025 ASTR….
0
14
0
RT @PennMedicine: #ASCO25: @StephenBagleyMD on CAR T cell for glioblastoma: “The treatment changed the trajectory of their disease.” Now in….
0
5
0
RT @UCSDCancer: The @NCCN Foundation has announced MCC member, Kathryn Tringale, MD, MAS, as a 2025 Young Investigator Award recipient. Th….
0
3
0
RT @michelle_monje: #CARTcells for #DIPG #DMG clinical trial (1st arm) results are out today. Full Tweetorial coming, but first want to sha….
0
159
0
Thanks, @HenningWillers! Great to present promising options for pts with locally advanced #lungcancer who are ineligible for chemoRT. @MSKCancerCenter @MSK_RadOnc.
1/2 .Promising outcomes of combining #radiotherapy and durvalumab without chemo in LA-NSCLC. PFS associated with PD-L1. Wonder if there is a path for personalized therapy where chemo can be dropped in high PDL1?. #ASTRO24
0
0
4
RT @MSK_RadOnc: 🧠☢️⚡️New in @JAMAOnc from @MSKCancerCenter #radonc grad Dr @EmilyLebow w/ Dr @yaoyu_md: Antibody-drug conjugates given conc….
0
6
0
RT @MSK_RadOnc: 🫁☢️New in @jitcancer from @MSKCancerCenter #radonc and @DanaFarber: This analysis of outcomes to #chemoradiation & #durval….
0
5
0
RT @BrainMets_MSK: Just out in @JAMAOnc - important data on risk factors for #brainmet necrosis with concurrent ADC + SRS: understanding se….
0
9
0
RT @yaoyu_md: Happy to share our work on SRS with concurrent ADCs, now out @JAMAOnc! In this study, led by @EmilyLebow, we investigated the….
jamanetwork.com
This cohort study investigates whether brain metastases that manifest after stereotactic radiotherapy with concurrent antibody-drug conjugates are associated with an increased risk of symptomatic...
0
17
0
RT @JAMAOnc: In this study, giving an antibody-drug conjugates (T-DXd, T-DM1, SG) concurrently with stereotactic radiotherapy was associate….
0
58
0
In @FrontiersIn we highlight the potential of #ctDNA to guide personalized therapy for patients with #lungcancer . Thank you @NateraOncology, @Natera, @YoninaMG , Bob Li, @danielrgomez44, Andreas Rimner & many more at @MSK_RadOnc @MSKCancerCenter!. 🔗
0
3
24
RT @gusviani: 🎙 SBRT for #sarcoma 🫁metastases achieved high rates of local control w/ low toxicity❗️🚨@OncoAlert @RadiotherapyOn1 .📌retro si….
0
22
0
RT @MSK_RadOnc: ☢️🫁 New in @RadiotherapyOn1 from Dr @EmilyLebow: We observed excellent long-term disease control with #SBRT for #sarcoma p….
0
21
0
RT @MSK_RadOnc: 🚨A #radonc away rotation @MSKCancerCenter means a month to explore the best of NYC: our cancer center, outstanding faculty….
0
8
0
RT @MSK_RadOnc: It's a Match! Welcome to @MSKCancerCenter #radonc!! 🥳 .🙌Kathryn Hockemeyer MD, PhD.🙌Gideon Haber, MD.🙌Elisa Liu, MD.🙌Revath….
0
14
0
RT @MSK_RadOnc: New from former @MSKCancerCenter #proton Dr @AnnaLeeMDMPH with @imrtlee: Compared with previous reports of photon-based #r….
0
13
0
RT @LungSummit: Study by @EmilyLebow, Narek Shaverdian & colleagues find high TMB status was associated with improved PFS after definitive….
0
8
0
RT @JAMANetworkOpen: Tumor mutational burden may be a novel biomarker to facilitate personalized radiotherapy for locally advanced lung can….
0
5
0
RT @MSK_RadOnc: 🚨New @JAMANetworkOpen PGY5 Dr @EmilyLebow: Tumor mutational burden-high status was associated with ⬆️ local-regional contro….
0
1
0
RT @brandon_imber: So proud of our amazing PGY5 @KathrynTringale helping to reinvigorate and modernize the use of #radiation for #pcnsl at….
0
9
0